{
  "actions": [
    {
      "acted_at": "2000-04-13", 
      "committee": "House Committee on Commerce", 
      "references": [], 
      "status": "REFERRED", 
      "text": "Referred to the House Committee on Commerce.", 
      "type": "referral"
    }, 
    {
      "acted_at": "2000-04-24", 
      "in_committee": "House Committee on Commerce", 
      "references": [], 
      "subcommittee": "Health and Environment", 
      "text": "Referred to the Subcommittee on Health and Environment.", 
      "type": "referral"
    }
  ], 
  "amendments": [], 
  "bill_id": "hres477-106", 
  "bill_type": "hres", 
  "committees": [
    {
      "activity": [
        "referral", 
        "in committee"
      ], 
      "committee": "House Commerce", 
      "committee_id": "HSIF"
    }, 
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Commerce", 
      "committee_id": "HSIF", 
      "subcommittee": "Subcommittee on Health and Environment", 
      "subcommittee_id": "04"
    }
  ], 
  "congress": "106", 
  "cosponsors": [], 
  "enacted_as": null, 
  "history": {
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2000-04-13", 
  "number": "477", 
  "official_title": "Expressing the sense of the House of Representatives regarding the disparity between identical prescription drugs sold in the United States, Canada, and Mexico.", 
  "popular_title": null, 
  "related_bills": [], 
  "short_title": null, 
  "sponsor": {
    "district": "2", 
    "name": "Baldacci, John Elias", 
    "state": "ME", 
    "thomas_id": "00048", 
    "title": "Rep", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2000-04-13", 
  "subjects": [
    "Canada", 
    "Commerce", 
    "Drug industry", 
    "Drugs", 
    "Health", 
    "Latin America", 
    "Mexico", 
    "Prescription pricing", 
    "Price policy"
  ], 
  "subjects_top_term": "Health", 
  "summary": {
    "as": "Introduced", 
    "date": "2000-04-13", 
    "text": "Expresses the sense of the House of Representatives that the cost disparity between identical prescription drugs sold in the United States, Canada, and Mexico should be reduced or eliminated."
  }, 
  "titles": [
    {
      "as": "introduced", 
      "title": "Expressing the sense of the House of Representatives regarding the disparity between identical prescription drugs sold in the United States, Canada, and Mexico.", 
      "type": "official"
    }
  ], 
  "updated_at": "2013-02-02T20:42:44-05:00"
}